TECENTRIQ® and ABRAXANE® - for Breast Cancer
TECENTRIQ® (Atezolizumab) and ABRAXANE® (Nab-Paclitaxel) - for adult patients with unresectable locally advanced or metastatic Triple Negative Breast Cancer (TNBC), whose tumors express PD-L1, as determined by an FDA-approved test.
TECENTRIQ® administered as an IV infusion over 60 minutes. If first infusion is tolerated, all subsequent infusions may be delivered over 30 minutes. Treatment given until disease progression or unacceptable toxicity
Drug Mode Given Standard Dose Days to Be Given Frequency Solution Volume Duration
TECENTRIQ® (Atezolizumab) IV 840 mg D1, D15 q28 NSS 250 ml 60 minutes
ABRAXANE® (Nab-Paclitaxel) IV 100 mg/m2 D1, D8, D15 q28 NSS As Dispensed 30 minutes